October 2014 tender notification
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2012/13 Invitation to Tender, dated 31 October 2012 and the 2013/14 Invitation to Tender, dated 07 November 2013.
Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms and Pharmacodes
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the 12th of the month prior to the date of subsidy change. More information and NOPC forms can be found on our website – https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/pharmaceutical-product-specifications-the-change-process
Where a product does not have a current Pharmacode, suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand before the 12th of the month prior to the date of listing. PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2013/14 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2017
CORRECTION to June 2014 tender notification: in bold and strikethrough
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
| Chemical name | Presentation; Pack size and type |
Current subsidy and (price) | New subsidy and price | Sole supply brand (Supplier) | Date of subsidy change | Sole Subsidised Supply date |
|---|---|---|---|---|---|---|
| Pyridoxine hydrochloride | tab 25 mg; 90 tablet, bottle |
$2.20 | PyridoxADE (BNM) |
1 November 2014 | 1 February 2015 |
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
Tenders awarded to listed pharmaceuticals where only the current brand is listed.
The decisions were as follows:
| Chemical Name | Presentation; Pack size and type |
Current pack price | New pack price | Hospital Supply Brand (Supplier) | DVLimit | Date of price change | Hospital Supply Status date |
|---|---|---|---|---|---|---|---|
| Pyridoxine hydrochloride | tab 25 mg; 90 tablet, bottle |
$2.20 | PyridoxADE (BNM) |
1% | 1 November 2014 | 1 January 2015 |
2012/13 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2016
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
| Chemical Name | Presentation;Pack size and type | Current subsidy and (price) | New subsidy and price | Sole supply brand (Supplier) | Date of listing/subsidy change for tender winning brand | Date of reference pricing of other listed brands | Sole Subsidised Supply date (and delisting of other listed brands) | Brand (Supplier) affected by reference pricing and delisting |
|---|---|---|---|---|---|---|---|---|
| Clobetasol propionate | crm 0.05%;30 g OP, tube | $3.68 | $3.20 | Clobetasol BNM(BNM) | 1 April 2015 | 1 June 2015 | 1 September 2015 | Dermol(Mylan) |
| Clobetasol propionate | oint 0.05%;30 g OP, tube | $3.68 | $3.20 | Clobetasol BNM(BNM) | 1 April 2015 | 1 June 2015 | 1 September 2015 | Dermol(Mylan) |
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
| Chemical Name | Presentation; Pack size and type |
Current pack price | New packprice | Hospital Supply Brand (Supplier) | DVLimit | Date of listing/price change for tender winning brand | Hospital Supply Status date (and delisting of other listed brands) | Brand (Supplier) to be delisted |
|---|---|---|---|---|---|---|---|---|
| Clobetasol propionate | crm 0.05%; 30 g, tube |
$3.68 | $3.20 | Clobetasol BNM (BNM) |
1% | 1 April 2015 | 1 June 2015 | Dermol (Mylan) |
| Clobetasol propionate | oint 0.05%; 30 g, tube |
$3.68 | $3.20 | Clobetasol BNM (BNM) |
1% | 1 April 2015 | 1 June 2015 | Dermol (Mylan) |
2013/14 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2017
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
Tenders awarded to pharmaceuticals where at least one other brand or pack size is listed.
The decisions were as follows:
| Chemical Name | Presentation; Pack size and type |
Current subsidy and (price) | New subsidy and price | Sole supply brand (Supplier) |
Date of listing/subsidy change for tender winning brand | Date of reference pricing of other listed brands | Sole Subsidised Supply date (and delisting of other listed brands) | Brand (Supplier) affected by reference pricing and delisting |
|---|---|---|---|---|---|---|---|---|
| Amlodipine | tab 5 mg; 250 tablet, bottle |
$2.65 per 100 tablets | $5.04 per 250 tablets | Apo-Amlodipine (Apotex) |
1 March 2015 | 1 May 2015 | 1 August 2015 | Apo-Amlodipine (100 tablet pack size) (Apotex) |
| Amlodipine | tab 10 mg; 250 tablet, bottle |
$4.15 per 100 tablets | $7.21 per 250 tablets | Apo-Amlodipine (Apotex) |
1 March 2015 | 1 May 2015 | 1 August 2015 | Apo-Amlodipine (100 tablet pack size) (Apotex) |
| Carvedilol 1. | tab 6.25 mg; 60 tablet, blister pack |
$21.00 per 30 tablets | $3.90 per 60 tablets | Dicarz (Mylan) |
1 April 2015 | 1 June 2015 | 1 September 2015 | Dilatrend (Roche) |
| Carvedilol 1. | tab 12.5 mg; 60 tablet, blister pack |
$27.00 per 30 tablets | $5.10 per 60 tablets | Dicarz (Mylan) |
1 April 2015 | 1 June 2015 | 1 September 2015 | Dilatrend (Roche) |
| Carvedilol 1. | tab 25 mg; 60 tablet, blister pack |
$33.75 per 30 tablets | $6.30 per 60 tablets | Dicarz (Mylan) |
1 April 2015 | 1 June 2015 | 1 September 2015 | Dilatrend (Roche) |
| Ezetimibe 2. | tab 10 mg; 30 tablet, blister pack |
$34.43 | $3.35 | Ezemibe (Mylan) |
1 June 2015 | 1 August 2015 | 1 November 2015 | Ezetrol (MSD) (was published as Mylan) |
| Ezetimibe with simvastatin 2.. | tab 10 mg with simvastatin 10 mg; 30 tablet, blister pack |
$36.68 | $5.15 | Zimybe (Mylan) |
1 June 2015 | 1 August 2015 | 1 November 2015 | Vytorin (MSD) |
| Ezetimibe with simvastatin 2 | tab 10 mg with simvastatin 20 mg; 30 tablet, blister pack |
$38.70 | $6.15 | Zimybe (Mylan) |
1 June 2015 | 1 August 2015 | 1 November 2015 | Vytorin (MSD) |
| Ezetimibe with simvastatin 2 | tab 10 mg with simvastatin 40 mg; 30 tablet, blister pack |
$41.40 | $7.15 | Zimybe (Mylan) |
1 June 2015 | 1 August 2015 | 1 November 2015 | Vytorin (MSD) |
| Ezetimibe with simvastatin 2 | tab 10 mg with simvastatin 80 mg; 30 tablet, blister pack |
$45.45 | $8.15 | Zimybe (Mylan) |
1 June 2015 | 1 August 2015 | 1 November 2015 | Vytorin (MSD) |
| 1. A Brand Switch Fee of $4.33 is payable from 1 September 2015 until 1 December 2015 2. A Brand Switch Fee of $4.33 is payable from 1 November 2015 until 1 February 2016 |
||||||||
Tenders awarded to listed pharmaceuticals where only the current brand is listed.
The decisions were as follows:
| Chemical name | Presentation; Pack size and type |
Current subsidy and (price) | New subsidy and price | Sole supply brand (Supplier) | Date of subsidy change | Sole Subsidised Supply date |
|---|---|---|---|---|---|---|
| Amlodipine | tab 2.5 mg; 100 tablet, bottle |
$2.45 | $2.21 | Apo-Amlodipine (Apotex) |
1 December 2014 | 1 March 2015 |
| Donepezil hydrochloride | tab 5 mg; 90 tablet, blister pack |
$7.71 | $5.48 | Donepezil-Rex (Rex Medical) |
1 December 2014 | 1 March 2015 |
| Donepezil hydrochloride | tab 10 mg; 90 tablet, blister pack |
$14.06 | $10.51 | Donepezil-Rex (Rex Medical) |
1 December 2014 | 1 March 2015 |
| Morphine sulphate | tab immediate-release 10 mg; 10 tablet, blister pack |
$2.80 | $2.80 | Sevredol (Douglas) |
1 February 2015 | 1 May 2015 |
| Morphine sulphate | tab immediate-release 20 mg; 10 tablet, blister pack |
$5.52 | $5.52 | Sevredol (Douglas) |
1 February 2015 | 1 May 2015 |
| Sodium citro-tartrate | grans effervescent 4 g sachets; 28 sachets |
$3.93 | $2.93 | Ural (Aspen) |
1 December 2014 | 1 March 2015 |
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
Tenders awarded to pharmaceuticals where at least one other brand or pack size is listed.
The decisions were as follows:
| Chemical Name | Presentation; Pack size and type |
Current pack price | New pack price | Hospital Supply Brand (Supplier) | DV Limit | Date of listing/price change for tender winning brand | Hospital Supply Status date (and delisting of other listed brands) | Brand (Supplier) to be delisted |
|---|---|---|---|---|---|---|---|---|
| Amlodipine | tab 5 mg; 250 tablet, bottle |
$2.65 per 100 tablets | $5.04 per 250 tablets | Apo-Amlodipine (Apotex) |
1% | 1 March 2015 | 1 May 2015 | Apo-Amlodipine (100 tablet pack size) (Apotex) |
| Amlodipine | tab 10 mg; 250 tablet, bottle |
$4.15 per 100 tablets | $7.21 per 250 tablets | Apo-Amlodipine (Apotex) |
1% | 1 March 2015 | 1 May 2015 | Apo-Amlodipine (100 tablet pack size) (Apotex) |
| Carvedilol | tab 6.25 mg; 60 tablet, blister pack |
$21.00 per 30 tablets | $3.90 per 60 tablets | Dicarz (Mylan) |
1% | 1 April 2015 | 1 June 2015 | Dilatrend (Roche) |
| Carvedilol | tab 12.5 mg; 60 tablet, blister pack |
$27.00 per 30 tablets | $5.10 per 60 tablets | Dicarz (Mylan) |
1% | 1 April 2015 | 1 June 2015 | Dilatrend (Roche) |
| Carvedilol | tab 25 mg; 60 tablet, blister pack |
$33.75 per 30 tablets | $6.30 per 60 tablets | Dicarz (Mylan) |
1% | 1 April 2015 | 1 June 2015 | Dilatrend (Roche) |
| Clarithromycin | inj 500 mg vial; 1 vial |
$30.00 | $20.40 | Martindale (Max health) |
1% | 1 January 2015 | 1 March 2015 | Klacid (Abbott Laboratories (NZ) Ltd) |
| Ezetimibe | tab 10 mg; 30 tablet, blister pack |
$34.43 | $3.35 | Ezemibe (Mylan) |
1% | 1 June 2015 | 1 August 2015 | Ezetrol (MSD) (was published as Mylan) |
| Ezetimibe with simvastatin | tab 10 mg with simvastatin 10 mg; 30 tablet, blister pack |
$36.68 | $5.15 | Zimybe (Mylan) |
1% | 1 June 2015 | 1 August 2015 | Vytorin (MSD) |
| Ezetimibe with simvastatin | tab 10 mg with simvastatin 20 mg; 30 tablet, blister pack |
$38.70 | $6.15 | Zimybe (Mylan) |
1% | 1 June 2015 | 1 August 2015 | Vytorin (MSD) |
| Ezetimibe with simvastatin | tab 10 mg with simvastatin 40 mg; 30 tablet, blister pack |
$41.40 | $7.15 | Zimybe (Mylan) |
1% | 1 June 2015 | 1 August 2015 | Vytorin (MSD) |
| Ezetimibe with simvastatin | tab 10 mg with simvastatin 80 mg; 30 tablet, blister pack |
$45.45 | $8.15 | Zimybe (Mylan) |
1% | 1 June 2015 | 1 August 2015 | Vytorin (MSD) |
| Imipenem with cilastatin | Inj 500 mg with cilastatin 500 mg; 30 ml vial |
$18.37 | $13.79 | Imipenem + Cilastatin RBX (Douglas) | 1% | 1 March 2015 | 1 May 2015 | Primaxin (MSD) |
Tenders awarded to listed pharmaceuticals where only the current brand is listed.
The decisions were as follows:
| Chemical Name | Presentation; Pack size and type |
Current pack price | New pack price | Hospital Supply Brand (Supplier) |
DV Limit | Date of price change | Hospital Supply Status date |
|---|---|---|---|---|---|---|---|
| Amlodipine | tab 2.5 mg; 100 tablet, bottle |
$2.45 | $2.21 | Apo-Amlodipine (Apotex) |
1% | 1 December 2014 | 1 February 2015 |
| Donepezil hydrochloride | tab 10 mg; 90 tablet, blister pack |
$14.06 | $10.51 | Donepezil-Rex (Rex-Medical) |
1% | 1 December 2014 | 1 February 2015 |
| Morphine sulphate | tab immediate-release 20 mg; 10 tablet, blister pack |
$5.52 | $5.52 | Sevredol (Douglas) |
1% | 1 February 2015 | 1 April 2015 |
| Donepezil hydrochloride | tab 5 mg; 90 tablet, blister pack |
$7.71 | $5.48 | Donepezil-Rex (Rex-Medical) |
1% | 1 December 2014 | 1 February 2015 |
| Morphine sulphate | tab immediate-release 10 mg; 10 tablet, blister pack |
$2.80 | $2.80 | Sevredol (Douglas) |
1% | 1 February 2015 | 1 April 2015 |
| Sodium citro-tartrate | grans effervescent 4 g sachets; 28 sachets |
$3.93 | $2.93 | Ural (Aspen) |
1% | 1 December 2014 | 1 February 2015 |
Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status
PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2012/13 Invitation to Tender, dated 31 October 2012 and 2013/14 Invitation to Tender, dated 07 November 2013:
2012/13 Invitation to Tender
| Chemical name | Line item |
|---|---|
| Dorzolamide hydrochloride with timolol maleate | Eye drops 2% with timolol maleate 0.5% |
| Latanoprost with timolol | Eye drops 50 mcg per ml with timolol 0.5% |
| Minocycline hydrochloride | Tab 50 mg |
| Oestradiol | TDDS 25 mcg per day |
| Oestradiol | TDDS 50 mcg per day |
| Oestradiol | TDDS 75 mcg per day |
| Oestradiol | TDDS 100 mcg per day |
| Sodium Cromoglycate | Eye drops 2% |
2013/14 Invitation to Tender
| Chemical name | Line item |
|---|---|
| Aqueous cream | Crm (100 g or less) |
| Aqueous cream | Crm (greater than 100 g) |
| Aripiprazole | Tab 10 mg |
| Aripiprazole | Tab 15 mg |
| Aripiprazole | Tab 20 mg |
| Aripiprazole | Tab 30 mg |
| Calcium folinate | Tab 15 mg |
| Chlorhexidine gluconate | Soln 4% |
| Cisplatin | Inj 1 mg per ml, 100 ml |
| Cisplatin | Inj 1 mg per ml, 50 ml |
| Citalopram hydrobromide | Tab 20 mg |
| Dipyridamole | Tab long-acting 150 mg |
| Fludarabine phosphate | Inj 50 mg |
| Fluorouracil sodium | Inj 50 mg per ml, 10 ml |
| Fluorouracil sodium | Inj 50 mg per ml, 20 ml |
| Fluorouracil sodium | Inj 50 mg per ml, 50 ml |
| Fluorouracil sodium | Inj 50 mg per ml, 100 ml |
| Ketamine | Inj 100 mg per ml, 2 ml vial |
| Mitozantrone | Inj 2 mg per ml, 10 ml |
| Mitozantrone | Inj 2 mg per ml, 12.5 ml |
| Norethisterone | Tab 5 mg |
| Oxybuprocaine hydrochloride | Eye drops 0.4%, single dose |
| Risperidone | Orally-disintegrating tablets 0.5 mg |
| Risperidone | Orally-disintegrating tablets 1 mg |
| Risperidone | Orally-disintegrating tablets 2 mg |
For products included in the 2012/13 or the 2013/14 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.